



Mar 27,
2019

Working

Hepatotoxicity during 6-thioguanine treatment: protocol for a systematic review

Linea Natalie Toksvang¹, Rikke Hebo Larsen¹, Thomas Leth Frandsen¹, Kjeld Schmiegelow², Cecilie Utke Rank³

¹Department of Paediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; ²Department of Paediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Institute of Clinical Medicine, The Faculty of Medicine, University of Copenhagen, Denmark. ; ³Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Pediatric Oncology Research Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

[dx.doi.org/10.17504/protocols.io.zjnf4me](https://doi.org/10.17504/protocols.io.zjnf4me)

 Linea Natalie Toksvang 

ABSTRACT

Hepatotoxicity was recognised as a complication of 6-thioguanine (6TG) in 1976. Since then, 6-TG associated hepatotoxicity in the form of acute sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease (VOD), has notably been reported in childhood acute lymphoblastic leukaemia (ALL), whereas chronic nodular regenerative hyperplasia (NRH) has been reported in adults with inflammatory bowel disease (IBD) as well as in childhood ALL. However, SOS and NRH should be considered part of a spectrum of microvascular disorders caused by endothelial injury. Nevertheless, the cellular mechanisms responsible for the sinusoidal damage, being pivotal to their development, remain to be established. 6TG-related SOS and NRH have been hypothesised to be dose-related, since they do not seem to occur with low cumulative doses.

The recent finding that higher levels of thioguanine nucleotides incorporated into leucocyte DNA (DNA-TGN) correlate to a lower relapse risk, calls for reappraisal of the feasibility of prolonged 6TG treatment for childhood ALL, while avoiding the risk of SOS and NRH.

Objectives

- Primary objective: To assess the incidence of hepatotoxicity in patients treated with 6TG compared to 6MP or standard care.
- Secondary objective: To explore if a safe dose of 6TG can be established.



6TGprotocol 221018.pdf

PROTOCOL STATUS

Working

We use this protocol in our group and it is working



This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited